Celecoxib and Erlotinib in Treating Patients With Liver Cancer

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT00293436
Phase
PHASE1/PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Celecoxib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Celecoxib may also stop the growth of liver cancer by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving celecoxib together with erlotinib and to see how well they work in treating patients with liver cancer.

Key Dates

First listed
Feb 17, 2006
Start date
Jan 31, 2005
Status verified
Sep 2012

Study Design

Enrollment
0 participants (actual)
Primary purpose
TREATMENT

Primary Outcome Measure

Safety (phase I)

Locations (1)

FacilityCityStateZIPSite coordinators
UCSF Comprehensive Cancer CenterSan FranciscoCalifornia94115-

Find similar trials in San Francisco, CA

By condition
Liver cancer
By specialty
OncologyGI oncologyHepatology
By research site
UCSF Comprehensive Cancer Center· San Francisco, CA

Related Studies